The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.

Abstract

Increasing evidence indicates that deregulation of RING-finger ubiquitin-protein ligases (E3s) involves in the development of hepatocellular carcinoma (HCC). These RING-finger E3s serve as oncoproteins or tumor suppressors in HCC under specific conditions. In this review, we summarize current knowledge about abnormal RING-finger E3s and their clinical significance in the development of HCC, and discuss parts of critical substrates for these RING-finger E3s in detail. Furthermore, in light of success of Bortezomib in treating hematological malignancies, we describe the preclinical and clinical studies of therapeutic approaches targeting aberrant RING-finger E3s in HCC.

• Authors: Jie Yin, Ji-Min Zhu, Xi-Zhong Shen
• Journal: International journal of cancer (Int J Cancer) Vol. 136 Issue 2 Pg. 249-57 (Jan 15 2015) ISSN: 1097-0215 [Electronic] United States
• PMID: 24420637 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2014 UICC.

Chemical References

• Antineoplastic Agents
• Ubiquitin-Protein Ligases
• Proteasome Endopeptidase Complex

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, enzymology)
• Humans
• Liver Neoplasms (drug therapy, enzymology)
• Molecular Targeted Therapy
• Proteasome Endopeptidase Complex (drug effects)
• RING Finger Domains
• Ubiquitin-Protein Ligases (antagonists & inhibitors, metabolism)